SHALBY145.25

Shalby Limited

· Pharma & Health
₹ CrorePeersGKSLGPTHEALTHINDRAMEDCOARTEMISMEDLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹1,562 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity8.290.633.723.72
Return on Assets5.190.111.891.89
Return on Capital Employed9.725.355.765.76
Return on Invested Capital6.702.072.853.15
Margins
EBITDA Margin18.9612.2012.5112.14
Operating Margin13.376.156.376.37
Incremental Operating Margin-37.8310.87
Pretax Margin13.735.135.314.90
Net Income Margin8.940.183.043.19
Net Income to Common Margin0.573.283.34
FCF Margin-2.95-6.97-13.06-13.06
Additional
Effective Tax Rate34.8696.5542.7234.89
Dvd Payout Ratio15.52675.050.00
Sustainable Growth Rate7.00-3.623.723.72
Incremental Operating Margin %-37.8310.87-6.23
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.